Tislelizumab as adjuvant therapy following endoscopic surgery for resectable recurrent nasopharyngeal carcinoma: A phase 2 randomized clinical trial.

Authors: Wanpeng Li, Tian Wang, Haoyuan Xu, Quan Liu, Hao Ding, Dehui Wang

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.e18078

Source: Full article

Abstract

e18078